Engineering the Brain Immune System for Tumor Therapy Abstract Brain glioblastoma multiforme (GBM) kills through glioma cells that infiltrate normal surrounding brain, with consequent displacement and destruction of healthy brain tissue. Therefore, even aggressive surgical resection fails to excise completely all infiltrating cells and provide long term survival. Alternatively, the immune system could specifically target infiltrating tumor cells using specific immune mediated homing mechanisms. However, the immune system has reduced activity in the brain, due to the brain's immune privilege, i.e. the blood-brain barrier, a lack of proper antigen presenting cells (i.e., dendritic cells, DCs) in the healthy brain, absence of classical lymphatic outflow channels, and local expression of the endogenous immune inhibitors, i.e., transforming growth factor beta. Nevertheless, experimental and clinical studies have shown that immune-therapy can effectively eradicate experimental GBM, and can be harnessed to develop novel therapies for human brain tumors. Recently, we have shown that gene transfer mediated modification of the brain immune microenvironment induces systemic anti-tumor immune responses. Specifically, expression of fms-like tyrosine kinase 3 ligand (Flt3L) recruits antigen presenting cells (e.g., dendritic cells, DCs) to the brain parenchyma and into the tumor mass. To increase the availability of tumor antigens to the DCs, tumor cells are killed using conditional cytotoxicity [herpes simplex virus type 1 thymidine kinase (TK) plus ganciclovir (GCV)]. This combined approach induces tumor regression, long-lasting systemic immunological memory, and long-term survival in animals with large syngeneic tumors. The overall goals of the experiments outlined in this proposal are to define the immune cells involved in this anti-GBM immune response, determine the origin and functional activities of brain DCs, and elucidate the specific mechanism(s) underlying their ability to induce systemic long-term anti-tumor immunity. Our hypothesis is that Flt3L and conditional cytotoxicity recruit a specific subtype of dendritic cells to the brain, i.e. plasmacytoid dendritic cells (pDCs), which leads to a systemic anti-tumor immune response. Understanding the mechanisms that stimulate this immune response from within the brain in situ will lead to novel treatments for one of the deadliest human cancers. The novelty of our approach is our capacity to specifically recruit pDCs to the brain parenchyma and the tumor microenvironment in response to expression of Flt3L, an approach that achieves the priming of a systemic immune response against GBM from within the tumor mass in situ. We hypothesize that this will maximize the generation of an effective anti-GBM immune response to GBM antigens.

Public Health Relevance

Gliobastoma multiforme (GBM) is a devastating brain tumor, for which there is no cure, and no significant improvements in patients'survival has occurred over the last 30 years. Using an intracranial brain tumor model we have shown that a novel combined conditional cytotoxic/immune-stimulatory gene therapy eliminates the growing tumor, and induces immunological memory which protects animals from tumor recurrence. Further, we have shown that any adverse side effects are limited, and reversible, with no long term permanent negative sequalae.
We aim to elucidate the cellular mechanisms which mediate these effects, the migration of immune cells into the tumor microenvironment and devise novel therapeutic approaches for this devastating cancer which will be implemented in phase I clinical trials.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-MDCN-F (02))
Program Officer
Fountain, Jane W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Schools of Medicine
Ann Arbor
United States
Zip Code
Candolfi, Marianela; Yagiz, Kader; Wibowo, Mia et al. (2014) Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. Clin Cancer Res 20:1555-65
Castro, Maria G; Baker, Gregory J; Lowenstein, Pedro R (2014) Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier! Clin Cancer Res 20:5147-9
Castro, Maria G; Candolfi, Marianela; Wilson, Thomas J et al. (2014) Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opin Biol Ther 14:1241-57
Mineharu, Yohei; Kamran, Neha; Lowenstein, Pedro R et al. (2014) Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions. Mol Cancer Ther 13:3024-36
Baker, Gregory J; Yadav, Viveka Nand; Motsch, Sebastien et al. (2014) Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia 16:543-61
Lowenstein, P R; Yadav, Viveka Nand; Chockley, Peter et al. (2014) There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease. Mol Ther 22:246-7
Lynes, John; Wibowo, Mia; Koschmann, Carl et al. (2014) Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H. Neurotherapeutics 11:623-35
VanderVeen, Nathan; Paran, Christopher; Appelhans, Ashley et al. (2014) Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors. Mol Ther Methods Clin Dev 1:
Assi, Hikmat H; Paran, Chris; VanderVeen, Nathan et al. (2014) Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy. J Pharmacol Exp Ther 349:458-69
Baker, Gregory J; Chockley, Peter; Yadav, Viveka Nand et al. (2014) Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Cancer Res 74:5079-90

Showing the most recent 10 out of 42 publications